OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Pharmacy and Pharmaceutical Sciences is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials	102
The need to redefine diabetic cardiomyopathy as a unique clinical entity that requires pharmacotherapy	80
Monkeypox: Virology, Pathophysiology, Clinical Characteristics, Epidemiology, Vaccines, Diagnosis, and Treatments	41
Evaluating the Effects of Agomelatine on Polysomnography Parameters in Patients with Obstructive Sleep Apnea.	36
Drug-disease interaction: Clinical consequences of inflammation on drugs action and disposition	34
Comparing broad and narrow phenotype algorithms: differences in performance characteristics and immortal time incurred	32
Corrigendum: Applications of exhaled breath condensate analysis for drug monitoring and bioequivalence study of inhaled drugs	30
Effect of Oregon grape root extracts on P-glycoprotein mediated transport in in vitro cell lines	26
Effect of Concomitant Drug Use on the Onset and Exacerbation of Diabetes Mellitus in Everolimus-Treated Cancer	23
Applications of Exhaled Breath Condensate Analysis for Drug Monitoring and Bioequivalence Study of Inhaled Drugs	21
Network pharmacology and molecular docking reveal the immunomodulatory mechanism of rhubarb peony decoction for the treatment of ulcerative colitis and irritable bowel syndrome	18
Pharmacological increases in circulating ketones fail to alleviate the hypertrophic cardiomyopathy present in the Tafazzin knockdown mouse model of Barth syndrome	18
Forkhead box O1 transcription factor; a therapeutic target for diabetic cardiomyopathy	17
From fasting to fat reshaping: exploring the molecular pathways of intermittent fasting-induced adipose tissue remodeling	16
Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System	16
Expanding the eligibility criteria for drugs in Canada’s time-limited health technology assessment and temporary drug access processes will further accelerate access to new medicines	16
Effects of dual therapy with betamethasone and tetracycline in a NC/Nga mouse model of atopic dermatitis	15
Real-world community hospital hyperglycemia management in noncritically ill, type 2 diabetic patients: a comparison between basal-bolus insulin and correctional insulin	15
Exploring the Role of Sodium-Glucose Cotransporter as a New Target for Cancer Therapy	14
Refined pharmacovigilance assessment of immune checkpoint inhibitors-related bullous pemphigoid: a multi-methodological approach utilizing FAERS database	14
Community pharmacists as antimicrobial resistance stewards: a narrative review on their contributions and challenges in low- and middle-income countries	13
Intrahepatic cholestasis of pregnancy associated with azathioprine: first quantitative disproportionality analysis using the FDA adverse event reporting system	12
Remdesivir-induced conduction abnormalities: A molecular model-based explanation	12
Gastrointestinal perforation associated with novel antineoplastic agents: A real-world study based on the FDA Adverse Event Reporting System	12
Metabolic flux in macrophages in obesity and type-2 diabetes	10

The Effect of HIV/AIDS Infection on the Clinical Outcomes of COVID-19: A Meta-Analysis	10
Development of a submicron emulsion-based delivery system to improve the anti-inflammatory activity of urolithin A	10
Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors’ perspective	10
Integration of real-world evidence from different data sources in health technology assessment	9